![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Virologic Response Rate in Egyptian HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Gamal Esmat1, Maissa El Raziky1, 2, Asmaa Gomaa3, Tamer Elbaz1, Mahmoud M. Abouelkhair1, 2, Alyaa Sabry3, Hadeel Gamal El Deen1, Mohamed K. Ashour1, 2, Mohammed Abdel-Hamid4, Ola Nada5, Sherine Helmy6, Hanaa Abdel-Maguid6, Richard Colonno7, Nathaniel Brown7, Eric Ruby7, Pamela Vig7, Imam Waked3
1Cairo University, 2Cairo Fatemic Hospital, 3National Liver Institute, 4Minia University, 5Ain Shams University, 6Pharco Pharmaceuticals and 7Presidio Pharmaceuticals
![AASLD1.gif](../images/112315/112315-6/AASLD1.gif)
![AASLD2.gif](../images/112315/112315-6/AASLD2.gif)
![AASLD3.gif](../images/112315/112315-6/AASLD3.gif)
![AASLD4.gif](../images/112315/112315-6/AASLD4.gif)
![AASLD5.gif](../images/112315/112315-6/AASLD5.gif)
![AASLD6.gif](../images/112315/112315-6/AASLD6.gif)
![AASLD7.gif](../images/112315/112315-6/AASLD7.gif)
![AASLD8.gif](../images/112315/112315-6/AASLD8.gif)
![AASLD9.gif](../images/112315/112315-6/AASLD9.gif)
![AASLD10.gif](../images/112315/112315-6/AASLD10.gif)
![AASLD11.gif](../images/112315/112315-6/AASLD11.gif)
![AASLD12.gif](../images/112315/112315-6/AASLD12.gif)
![AASLD13.gif](../images/112315/112315-6/AASLD13.gif)
![AASLD14.gif](../images/112315/112315-6/AASLD14.gif)
![AASLD15.gif](../images/112315/112315-6/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|